GSK wins $235m from Teva in patent trial – report

A jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, Reuters reported.

Court documents showed a federal jury in Wilmington, Delaware, found that Teva willfully infringed the patent in connection with its sales of a generic version of Coreg with a label indicating it could be used for treating chronic heart failure, Reuters reported.

“We still intend to present our equitable defenses to the court at a separate hearing which could eliminate the liability determination or significantly reduce the assessed damages,” said Teva in a statement.

“We are also considering an appeal.”